Journal DOI 10.68956/journal.human-performance-futures

Creative Commons source reading · Machine learning for performance

Machine Learning-Based QSAR Models for Discovery of Inhibitors Targeting Leishmania infantum Amastigotes

Flores-Balmaseda N; Rojas-Vargas JA; Rojas-Socarrás S; Pérez-Giménez F; Torrens F; Castillo-Garit JA

Originally published in Pharmaceuticals (Basel) · 2026-04-07

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

AbstractBackground/Objectives: Leishmaniasis is a group of diseases caused by obligate intracellular parasites of the Leishmania genus and is classified by the World Health Organization as a category I neglected tropical disease. Leishmania infantum predominantly affects children under five years of age and shows an increasing incidence of cutaneous and visceral forms. The development of new therapeutic alternatives remains challenging, making in silico approaches valuable for accelerating antileishmanial drug discovery. This study aimed to identify new compounds with potential activity against Leishmania infantum amastigotes using artificial intelligence-based classification models. Methods: A curated database of compounds with reported biological activity was constructed. Molecular representation employed zero- to two-dimensional…

4. Conclusions

In this study, we developed and validated a set of machine learning-based QSAR models for the identification of compounds with potential activity against Leishmania infantum amastigotes. By integrating rigorous data curation, diversity-aware dataset splitting, algorithm-specific descriptor selection, multi-level validation, and consensus-based virtual screening, we established a robust and interpretable computational framework for the prioritization of antileishmanial candidates. The application of this framework to a dataset of more than 5000 compounds enabled the identification of a reduced set of high-confidence candidates, including DrugBank molecules with known pharmacological profiles and structurally diverse synthetic compounds. The pharmacological interpretation of the predicted hits and the analysis of relevant molecular…

Editorial reading guide

  • What data created and tested the model, and was evaluation independent?
  • What is the cost of a false positive, false negative or out-of-distribution decision?